Atkore has seen a 21% run-up since we initiated BUY coverage on the stock in March 2023. Atkore’s valuation is still reasonable and there is still some upside. Our longer-term thesis remains intact.
Teradyne's recent share price decline offers an attractive investment opportunity with a potential upside of more than 40%, providing indirect exposure to the AI industry. Despite short-term ...
We maintain our fair value estimate of HKD 64 for JD Health 06618 after the company reported second-half revenue of CNY 26.5 billion, which was better than the top range of guidance of CNY 23.9 ...
Despite dramatic swings, the long-term trend for artificial intelligence remains intact, according to BMO Wealth Management chief market strategist Carol Schleif. Following a steep 1,200-point decline ...
Intact Financial stock is drawing interest for its long-term growth strategy in property and casualty insurance. The Canadian group has grown largely through disciplined acquisitions and underwriting, ...